Aberrant expression of peroxiredoxin subtypes in neurodegenerative disorders

An increasing body of evidence indicates that oxidative stress and damage play a role in the pathogenesis of a number of diseases associated with neurodegeneration, including Down syndrome (DS), Alzheimer's disease (AD) and Pick's disease (PD). Although oxidative stress is a common element in these diseases, specific clinico-pathological phenotypes have been described for each disorder. Development of these phenotypes might be linked, among others, to differences in antioxidant response. The present study is designed to investigate expression of peroxiredoxins (Prxs), the newly characterized family of highly conserved antioxidant enzymes, and other antioxidant enzymes in frontal cortex and cerebellum of DS, AD and PD patients using the technique of proteomics. Levels of Prx I, Mn superoxide dismutase (SOD2) and glutathione-S-transferase omega1 in DS, AD and PD were not significantly different from that of controls in both brain regions investigated. In contrast, Prx II was significantly increased (P<0.05) in frontal cortex of DS, AD and PD, whereas Prx III was decreased in frontal cortex of DS (P<0.01) and PD (P<0.001). Interestingly, Prx VI displayed a significant increase (P<0.05) only in PD frontal cortex. The present data indicate that differential regulation of antioxidant enzymes exist in DS, AD and PD, suggestive of the diversity as well as distinct functional roles of these proteins. Moreover, while up-regulation of Prx II appears to provide evidence for the existence of compensatory response in increased cell loss, up-regulation of Prx VI may be used to discriminate PD from AD as well as DS.

[1]  C. Sen,et al.  Antioxidant and redox regulation of gene transcription , 1996, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  J. Wands,et al.  P53- and CD95-associated apoptosis in neurodegenerative diseases. , 1998, Laboratory investigation; a journal of technical methods and pathology.

[3]  S. Rhee,et al.  Characterization of a Mammalian Peroxiredoxin That Contains One Conserved Cysteine* , 1998, The Journal of Biological Chemistry.

[4]  B. Morgan,et al.  Thioredoxin peroxidase is required for the transcriptional response to oxidative stress in budding yeast. , 2000, Molecular biology of the cell.

[5]  S. Rhee,et al.  Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. , 1999, Methods in enzymology.

[6]  D. O’Rourke,et al.  Murine thioredoxin peroxidase delays neuronal apoptosis and is expressed in areas of the brain most susceptible to hypoxic and ischemic injury. , 1997, DNA and cell biology.

[7]  J. Schwartz,et al.  Molecular and Biochemical Reprogramming of Oncogenesis through the Activity of Prooxidants and Antioxidants , 1993, Annals of the New York Academy of Sciences.

[8]  J. Haffmans,et al.  Differential epileptogenic potentials of selectiveμ andδ opiate receptor agonists , 1983, Journal of Neural Transmission.

[9]  H. Langen,et al.  Identification of proteins by matrix-assisted laser desorption ionization-mass spectrometry following in-gel digestion in low-salt, nonvolatile buffer and simplified peptide recovery. , 1997, Analytical biochemistry.

[10]  G Chelvanayagam,et al.  Identification, Characterization, and Crystal Structure of the Omega Class Glutathione Transferases* , 2000, The Journal of Biological Chemistry.

[11]  W. Snow,et al.  The NINCDS‐ADRDA Work Group criteria for the clinical diagnosis of probable Alzheimer's disease , 1988, Neurology.

[12]  H. Vinters,et al.  Differential expression of peroxiredoxin subtypes in human brain cell types , 1999, Journal of neuroscience research.

[13]  J. Trojanowski,et al.  Oxidation of Cytosolic Proteins and Expression of Creatine Kinase BB in Frontal Lobe in Different Neurodegenerative Disorders , 1999, Dementia and Geriatric Cognitive Disorders.

[14]  J. de Vellis,et al.  Thioredoxin peroxidase (natural killer enhancing factor) regulation of activator protein-1 function in endothelial cells. , 1998, Biochemical and biophysical research communications.

[15]  D. S. St. Clair,et al.  Nuclear factor kappaB-dependent mechanisms coordinate the synergistic effect of PMA and cytokines on the induction of superoxide dismutase 2. , 2001, The Biochemical journal.

[16]  H. Langen,et al.  Effect of protein application mode and acrylamide concentration on the resolution of protein spots separated by two‐dimensional gel electrophoresis , 1997, Electrophoresis.

[17]  G. Perry,et al.  Role of Oxidative Stress in Frontotemporal Dementia , 1999, Dementia and Geriatric Cognitive Disorders.

[18]  S. Phelan.  AOP2 (antioxidant protein 2): structure and function of a unique thiol-specific antioxidant. , 1999, Antioxidants & redox signaling.

[19]  J. Cadet.  Free radicals and neurodegeneration , 1994, Trends in Neurosciences.

[20]  G. Lubec.  The hydroxyl radical: from chemistry to human disease. , 1996, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

[21]  M. M. Bradford.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. , 1976, Analytical biochemistry.

[22]  S. Rhee,et al.  Identification of a New Type of Mammalian Peroxiredoxin That Forms an Intramolecular Disulfide as a Reaction Intermediate* , 2000, The Journal of Biological Chemistry.

[23]  Eun Sug Park,et al.  Role of Peroxiredoxins in Regulating Intracellular Hydrogen Peroxide and Hydrogen Peroxide-induced Apoptosis in Thyroid Cells* , 2000, The Journal of Biological Chemistry.

[24]  I. Fridovich.  The biology of oxygen radicals. , 1978, Science.

[25]  D. L. Le Couteur,et al.  Immunohistochemistry of Omega Class Glutathione S-Transferase in Human Tissues , 2001, Journal of Histochemistry and Cytochemistry.

[26]  N. Cairns,et al.  Expression of apoptosis related proteins: RAIDD, ZIP kinase, Bim/BOD, p21, Bax, Bcl-2 and NF- k B in brains of patients with Down syndrome , 2001 .

[27]  T. Squier,et al.  Oxidative stress and protein aggregation during biological aging , 2001, Experimental Gerontology.

[28]  M. Story,et al.  The Cloning and Characterization of a New Stress Response Protein , 1999, The Journal of Biological Chemistry.

[29]  S. Monte.  Molecular abnormalities of the brain in Down syndrome: relevance to Alzheimer's neurodegeneration. , 1999 .

[30]  D. Dickson.  Neuropathology of Pick’s disease , 2001, Neurology.

[31]  C. Masters,et al.  Reactive oxygen species and Alzheimer's disease. , 1997, Biochemical pharmacology.

[32]  M. Fountoulakis.  Proteomics: Current technologies and applications in neurological disorders and toxicology , 2001, Amino Acids.

[33]  N. Cairns,et al.  The reduction of NADH ubiquinone oxidoreductase 24- and 75-kDa subunits in brains of patients with Down syndrome and Alzheimer's disease. , 2001, Life sciences.

[34]  C. Dodia,et al.  1-Cys Peroxiredoxin, a Bifunctional Enzyme with Glutathione Peroxidase and Phospholipase A2 Activities* , 2000, The Journal of Biological Chemistry.

[35]  L. Butterfield,et al.  From cytoprotection to tumor suppression: the multifactorial role of peroxiredoxins. , 1999, Antioxidants & redox signaling.

[36]  L. Obeid,et al.  Thioredoxin Peroxidase Is a Novel Inhibitor of Apoptosis with a Mechanism Distinct from That of Bcl-2* , 1997, The Journal of Biological Chemistry.

[37]  I. Kola,et al.  Oxidative stress and neural dysfunction in Down syndrome. , 1999, Journal of neural transmission. Supplementum.

[38]  E. Warrington,et al.  Provisional clinical and neuroradiological criteria for the diagnosis of Pick's disease , 1998 .

[39]  L. Chylack,et al.  Transcriptional Regulation of the Antioxidant Protein 2 Gene, a Thiol-specific Antioxidant, by Lens Epithelium-derived Growth Factor to Protect Cells from Oxidative Stress* , 2001, The Journal of Biological Chemistry.

[40]  A. Posada,et al.  Relationships between neuronal death and the cellular redox status. Focus on the developing nervous system , 1999, Progress in Neurobiology.

[41]  M. Beal.  Mitochondria, free radicals, and neurodegeneration , 1996, Current Opinion in Neurobiology.

[42]  Y. Liu,et al.  Neuronal and glial DNA fragmentation in Pick’s disease , 1999, Acta Neuropathologica.

[43]  H. Affolter,et al.  The 5-hydroxytryptamine receptor of blood platelets , 2005, Journal of Neural Transmission.

[44]  G. Powis,et al.  Thioredoxin peroxidase-1 (peroxiredoxin-1) is increased in thioredoxin-1 transfected cells and results in enhanced protection against apoptosis caused by hydrogen peroxide but not by other agents including dexamethasone, etoposide, and doxorubicin. , 2001, Archives of Biochemistry and Biophysics.

[45]  N. Cairns,et al.  Protein levels of human peroxiredoxin subtypes in brains of patients with Alzheimer's disease and Down syndrome. , 2001, Journal of neural transmission. Supplementum.

[46]  G. Lubec,et al.  Antioxidant proteins in fetal brain: superoxide dismutase-1 (SOD-1) protein is not overexpressed in fetal Down syndrome. , 2001, Journal of neural transmission. Supplementum.

[47]  C. Cotman,et al.  Apoptosis Decision Cascades and Neuronal Degeneration in Alzheimer’s Disease , 1998, Neurobiology of Aging.

[48]  N. Cairns,et al.  Superoxide Dismutase SOD1, Encoded on Chromosome 21, but Not SOD2 Is Overexpressed in Brains of Patients With Down Syndrome , 2001, Journal of Investigative Medicine.

[49]  S. Rhee,et al.  Mammalian Peroxiredoxin Isoforms Can Reduce Hydrogen Peroxide Generated in Response to Growth Factors and Tumor Necrosis Factor-α* , 1998, The Journal of Biological Chemistry.

[50]  Anibal E. Vercesi,et al.  The Thiol-specific Antioxidant Enzyme Prevents Mitochondrial Permeability Transition , 1998, The Journal of Biological Chemistry.

[51]  John Q. Trojanowski,et al.  The neuropathology of dementia , 2004 .

[52]  S. M. Sumi,et al.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD) , 1991, Neurology.

[53]  Barry Halliwell,et al.  Reactive Oxygen Species and the Central Nervous System , 1992, Journal of neurochemistry.

[54]  N Taniguchi,et al.  Peroxiredoxin IV is a secretable protein with heparin-binding properties under reduced conditions. , 2000, Journal of biochemistry.

[55]  N. Cairns,et al.  Alteration of caspases and apoptosis-related proteins in brains of patients with Alzheimer's disease. , 2001, Biochemical and biophysical research communications.

[56]  G. Church,et al.  Cloning and sequencing of thiol-specific antioxidant from mammalian brain: alkyl hydroperoxide reductase and thiol-specific antioxidant define a large family of antioxidant enzymes. , 1994, Proceedings of the National Academy of Sciences of the United States of America.